Nov 13, 2019 / 06:30PM GMT
Vikramjeet Singh Chopra - Crédit Suisse AG - Research Division - Research Analyst
Good afternoon, everyone. My name is Vik Chopra at -- with Crédit Suisse. Very happy to have Mr. Willie Quinn, the CFO of Sunesis Pharmaceuticals. Thanks for being with us.
William P. Quinn - Sunesis Pharmaceuticals, Inc. - Senior VP of Finance & Corporate Development and CFO
Good afternoon. Happy to be here and give you a quick update on Sunesis Pharmaceuticals. Before I begin, I want to remind everyone that I will be making forward-looking statements, and you should review our filings with the SEC for more details, our most recent 10-Q was filed for the quarter ended September 30, 2019.
Sunesis is an oncology development company focused on kinase inhibitors. We have an exciting noncovalent BTK inhibitor in development, and I'll spend most of my time talking about that. We also have a PDK1 inhibitor. I'll tell you a little bit about that. And then we have a pan-Raf inhibitor, which is currently in the hands of Takeda, and they are
Sunesis Pharmaceuticals Inc at Credit Suisse Healthcare Conference - Scottsdale Transcript
Nov 14, 2019
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers